TABLE 5 RT-PCR, PCR, ISH, and IHC Results in the Study Group

Patient No.	Tissue Specimen	MCL	RT-PCR	t(11;14)	ISH	IHC^a
1	LN	CV	P	ND	P	N
2	LN	CV	ND	P	P	P
3	LN	CV	ND	P	ND	P
4	LN	CV	ND	P	P	N
5	LN	CV	P	ND	P	P
6	LN	CV	P	ND	P	N
7	LN	CV	P	N	P	P
8	LN	CV	P	P	P	P
9	LN	CV	ND	N	P	P
10	LN	CV	P	P	P	P
11	LN	CV	N	ND	N	N
12	LN	CV	N	N	N	N
13	LN	CV	P	N	N	N
14	LN	CV	ND	N	P	P
15	Palate^b	CV	P	N	P	P
16	LN	BV	ND	ND	N	N
17	LN	BV	P	P	P	P
18	LN	BV	P	P	P	P
19	LN	BV	P	N	P	P
20	LN	BV	P	N	P	P
21	LN	BV	P	P	P	P
22	LN	BV	P	P	P	P
23	LN	BV	P	ND	ND	ND
24	Nasopharynx^b	BV	ND	N	P	P
25	Skin	BV	ND	N	P	N
26	BMB	CV	ND	N	ND	P
26	Small intestine	CV	P(ni)	N	ND	ND
26	Stomach	CV	P(ni)	P	P	P
27	LN	CV	P	N	P	N
27	Liver	CV	P(ni)	P	P	N
27	Spleen	CV	P	P	P	N
28	Stomach	CV	ND	P	P	P
28	BMB	CV	ND	P	P	N
29	LN	CV	ND	P	P	P
29	BMB	CV	ND	P	P	P
30	Stomach	CV	P(ni)	P	P	P
30	LN	CV	ND	P	P	P

BV, blastoid variant; CV, centrocytoid variant; IHC, immunohistochemistry; ISH, in situ hybridization; LN, lymph node; MCL, mantle cell lymphoma; N, negative; ND, not done; P, positive; PCR, polymerase chain reaction; P(ni), patients positive for cyclin D1 but noninformative because of tissue elements normally expressing this gene; RT-PCR, reverse transcriptase-PCR.
^aNuclear staining in >50% of the neoplastic cell population.
^bWithout epithelium.

Quick links

Search